Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs
Abstract
:1. Introduction
2. Materials and Methods
2.1. Sample
2.2. Recruitment, Enrollment, and Compensation
2.3. Measures
2.4. Analyses
3. Results
3.1. Descriptive Analyses
3.2. Bivariate Analyses
3.2.1. Change in Primary Source of Income
3.2.2. Loss of Source of Income
3.2.3. Change in Housing Situation
3.3. Adjusted Logistic Regression Analyses
3.3.1. Change in Primary Source of Income
3.3.2. Loss of Source of Income
3.3.3. Change in Housing Situation
4. Discussion
4.1. Reports of Increased Overdose Risks among PWID during the First 15 Months of the Pandemic
4.2. Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Castaldelli-Maia, J.M.; Marziali, M.E.; Lu, Z.; Martins, S.S. Investigating the effect of national government physical distancing measures on depression and anxiety during the COVID-19 pandemic through meta-analysis and meta-regression. Psychol. Med. 2021, 51, 881–893. [Google Scholar] [CrossRef]
- Kola, L.; Kohrt, B.A.; Hanlon, C.; Naslund, J.A.; Sikander, S.; Balaji, M.; Benjet, C.; Cheung, E.Y.L.; Eaton, J.; Gonsalves, P.; et al. COVID-19 mental health impact and responses in low-income and middle-income countries: Reimagining global mental health. Lancet Psychiatry 2021, 8, 535–550. [Google Scholar] [CrossRef]
- Levy Yeyati, E.; Filippini, F. Social and Economic Impact of COVID-19. (Brookings Global Working Paper #158). Global Economy and Development at Brookings. 2021. Available online: https://www.brookings.edu/wp-content/uploads/2021/06/Social-and-economic-impact-COVID.pdf (accessed on 5 August 2021).
- Zhang, Y.; Lange, K.W. Coronavirus disease 2019 (COVID-19) and global mental health. Glob. Health J. 2021, 5, 31–36. [Google Scholar] [CrossRef]
- Vasylyeva, T.I.; Smyrnov, P.; Strathdee, S.; Friedman, S.R. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J. Int. AIDS Soc. 2020, 23, e25583. [Google Scholar] [CrossRef]
- Genberg, B.L.; Astemborski, J.; Piggott, D.A.; Woodson-Adu, T.; Kirk, G.D.; Mehta, S.H. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Baltimore, Maryland. Drug Alcohol. Depend. 2021, 221, 108584. [Google Scholar] [CrossRef]
- Gleason, E.; Nolan, N.S.; Marks, L.R.; Habrock, T.; Liang, S.Y.; Durkin, M.J. Barriers to Care Experienced by Patients who Inject Drugs during the COVID-19 Pandemic: A Qualitative Analysis. J. Addict. Med. 2021, 16, e133. [Google Scholar] [CrossRef]
- Bartholomew, T.S.; Nakamura, N.; Metsch, L.R.; Tookes, H.E. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int. J. Drug Policy 2020, 83, 102821. [Google Scholar] [CrossRef]
- Alter, A.; Yeager, C. COVID-19 Impact on US National Overdose Crisis; University of Baltimore Center for Drug Policy and Enforcement: Baltimore, MD, USA, 2020; Available online: https://www.odmap.org:4443/Content/docs/news/2020/ODMAP-Report-June-2020.pdf (accessed on 16 July 2021).
- Ochalek, T.A.; Cumpston, K.L.; Wills, B.K.; Gal, T.S.; Moeller, F.G. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA 2020, 324, 1673–1674. [Google Scholar] [CrossRef] [PubMed]
- Slavova, S.; Rock, P.; Bush, H.M.; Quesinberry, D.; Walsh, S.L. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol. Depend. 2020, 214, 108176. [Google Scholar] [CrossRef]
- Davidson, P.J.; McLean, R.L.; Kral, A.H.; Gleghorn, A.A.; Edlin, B.R.; Moss, A.R. Fatal heroin-related overdose in San Francisco, 1997–2000: A case for targeted intervention. J. Urban Health 2003, 80, 261–273. [Google Scholar] [CrossRef] [Green Version]
- Lamonica, A.K.; Boeri, M.; Turner, J. Circumstances of overdose among suburban women who use opioids: Extending an urban analysis informed by drug, set, and setting. Int. J. Drug Policy 2021, 90, 103082. [Google Scholar] [CrossRef]
- Carroll, J.J.; Rich, J.D.; Green, T.C. The protective effect of trusted dealers against opioid overdose in the US. Int. J. Drug Policy 2020, 78, 102695. [Google Scholar] [CrossRef]
- Croxford, S.; Emanuel, E.; Ibitoye, A.; Njoroge, J.; Edmundson, C.; Bardsley, M.; Heinsbroek, E.; Hope, V.; Phipps, E. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. Public Health 2021, 192, 8–11. [Google Scholar] [CrossRef]
- Cameron-Krepp, S.; Hall, C.; Dietze, P. Impact of COVID-19 and Associated Restrictions on People Who Inject Drugs in Victoria: Findings from the Illicit Drug Reporting System 2020; Drug Trends Bulletin Series; National Drug and Alcohol Research Centre, UNSW: Sydney, Australia, 2020. [Google Scholar]
- Lindqvist, K.; Wallmofeldt, C.; Holmén, E.; Hammarberg, A.; Kåberg, M. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic. Harm Reduct. J. 2021, 18, 52. [Google Scholar] [CrossRef]
- Jemberie, W.B.; Williams, J.S.; Eriksson, M.; Grönlund, A.S.; Ng, N.; Nilsson, M.B.; Padyab, M.; Priest, K.C.; Sandlund, M.; Snellman, F.; et al. Substance use disorders and COVID-19: Multi-faceted problems which require multi-pronged solutions. Front. Psychiatry 2020, 11, 714. [Google Scholar] [CrossRef]
- Rudolph, K.E.; Kinnard, E.N.; Aguirre, A.R.; Goin, D.E.; Feelemyer, J.; Fink, D.; Cerda, M. The relative economy and drug overdose deaths. Epidemiology 2020, 31, 551–558. [Google Scholar] [CrossRef]
- Sachdev, D.; Mara, E.; Hsu, L.; Scheer, S.; Rutherford, G.; Enanoria, W.; Gandhi, M. COVID-19 susceptibility and outcomes among people living with HIV in San Francisco. J. Acquir. Immune Defic. Syndr. 2021, 86, 19–21. [Google Scholar] [CrossRef] [PubMed]
- Mistler, C.B.; Curley, C.M.; Rosen, A.O.; El-Krab, R.; Wickersham, J.A.; Copenhaver, M.M.; Khati, A.; Shrestha, R. The Impact of COVID-19 on Access to HIV Prevention Services among Opioid-Dependent Individuals. J. Community Health 2021, 46, 960–966. [Google Scholar] [CrossRef] [PubMed]
- Zang, X.; Krebs, E.; Chen, S.; Piske, M.; Armstrong, W.S.; Behrends, C.N.; Del Rio, C.; Feaster, D.J.; Marshall, B.D.; Mehta, S.H.; et al. The potential epidemiological impact of coronavirus disease 2019 (COVID-19) on the human immunodeficiency virus (HIV) epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in 6 US cities. Clin. Infect. Dis. 2021, 72, e828–e834. [Google Scholar] [CrossRef]
- Adams, M.; Sionean, C.; Broz, D.; Lewis, R.; Wejnert, C. Serious Mental Illness Among Young People Who Inject Drugs: An Assessment of Injection Risks and Healthcare Use. J. Infect. Dis. 2020, 222 (Suppl. S5), S401–S409. [Google Scholar] [CrossRef]
- Mackesy-Amiti, M.E.; Donenberg, G.R.; Ouellet, L.J. Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol. Depend. 2012, 124, 70–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rothman, K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1, 43–46. [Google Scholar] [CrossRef] [Green Version]
N | % | |
---|---|---|
Gender | ||
Male | 96 | 69.6% |
Female | 37 | 26.8% |
Transgender | 1 | 0.7% |
Missing Data | 4 | 2.9% |
Age | ||
18–24 | 14 | 10.1% |
25–30 | 91 | 65.9% |
31+ | 30 | 21.7% |
Missing Data | 3 | 2.2% |
Race/ethnicity | ||
Non-Hispanic Black | 7 | 5.1% |
Hispanic | 41 | 29.7% |
Non-Hispanic White | 79 | 57.2% |
Non-Hispanic Other or Mixed Race | 7 | 5.1% |
Missing Data | 4 | 2.9% |
City of Residence | ||
Chicago | 53 | 38.4% |
Other, suburban | 85 | 61.6% |
Missing Data | 0 | 0.0% |
History of COVID-19 Positivity | ||
Yes | 2 | 4.2% |
No | 46 | 95.8% |
Not asked, because we introduced this question into the survey after these participants had already completed it | 90 | |
Timing of Interview | ||
April 2020–June 2020 | 29 | 21.0% |
July 2020–September 2020 | 35 | 25.4% |
October 2020–December 2020 | 30 | 21.7% |
January 2021–March 2021 | 19 | 13.8% |
April 2021–June 2021 | 25 | 18.1% |
N (Valid %) of Participants Experiencing Risk | N Missing | Cross Tabulation by Change in Primary Source of Income: (p-Value from Fisher’s Exact Test) | Cross Tabulation by Loss of Source of Income: (p-Value from Fisher’s Exact Test) | Cross Tabulation by Change in Housing Situation: (p-Value from Fisher’s Exact Test) | |
---|---|---|---|---|---|
Reported Wanting to Use More than before Pandemic * | 64 (48.1%) | 5 | (p = 0.074) | (p = 0.070) | (p = 0.294) |
Reported Actually Using More than Usual * | 55 (42.3%) | 8 | (p = 0.032) | (p = 0.011) | (p = 0.405) |
Reported Using More by Themselves than Usual * | 65 (50.4%) | 9 | (p = 0.013) | (p = 0.167) | (p = 0.169) |
Reported Worrying about Overdosing During the Pandemic * | 21 (16.2%) | 8 | (p = 0.089) | (p = 0.500) | (p = 0.057) |
Reported Having Different Triggers for Using than Usual | 54 (40.6%) | 5 | (p = 0.122) | (p = 0.084) | (p =0.246) |
Reported Experiencing New or Worsening Mental Health Problems or Symptoms | 34 (24.6%) | 1 | (p = 0.242) | (p = 0.547) | (p = 0.775) |
Reported Having More Difficulty Accessing Mental Health Services | 21 (52.5%) | 98 | (p = 0.107) | (p = 0.025) | (p = 0.062) |
Reported Increasing the Number of Times Injected Per Day * | 36 (28.3%) | 11 | (p = 0.329) | (p = 0.336) | (p = 0.464) |
Reported a Decrease in Purity of Drugs Purchased * | 52 (40.3%) | 9 | (p = 0.552) | (p = 0.205) | (p = 0.136) |
Reported a Decrease in Quality of Drugs Purchased * | 52 (40.6%) | 10 | (p = 0.529) | (p = 0.429) | (p = 0.341) |
Reported More Fentanyl in Drugs Purchased * | 38 (31.1%) | 16 | (p = 0.325) | (p = 0.529) | (p = 0.121) |
Reported Amount of Drugs Used Alone Has Increased Since Start of Pandemic * | 36 (28.1%) | 10 | (p = 0.413) | (p = 0.048) | (p = 0.546) |
Reported that Amount of Worrying about Overdosing Has Increased * | 22 (17.2%) | 10 | (p = 0.066) | (p = 0.267) | (p = 0.581) |
Reported Having More Triggers than Normal * | 36 (27.5%) | 7 | (p = 0.238) | (p = 0.487) | (p = 0.488) |
Reported Trying to Stop but Being Unable * | 28 (22.0%) | 11 | (p = 0.085) | (p = 0.036) | (p = 0.411) |
Outcome Variable | N (Valid %) of Participants Experiencing Risk | N Missing | Regression Predictor: Change in Primary Source of Income: Odds Ratio (p-Value) | Regression Predictor: Loss of Source of Income: Odds Ratio (p-Value) | Regression Predictor: Change in Housing Situation: Odds Ratio (p-Value) |
---|---|---|---|---|---|
Reported Wanting to Use More than before Pandemic * | 42 (45.7%) | 0 | 1.41 (p = 0.343) | 1.70 (p = 0.240) | 0.52 (p = 0.337) |
Reported Actually Using More than Usual * | 37 (41.6%) | 3 | 2.31 (p = 0.093) | 2.63 (p = 0.043) | 1.90 (p = 0.365) |
Reported Using More by Themselves than Usual * | 42 (48.3%) | 5 | 2.82 (p = 0.032) | 1.60 (p = 0.299) | 1.87 (p = 0.365) |
Reported Worrying about Overdosing During the Pandemic * | 13 (14.8%) | 4 | 5.24 (p = 0.076) | 1.79 (p = 0.442) | 8.76 (p = 0.032) |
Reported Having Different Triggers for Using than Usual | 35 (38.5%) | 1 | 1.31 (p = 0.579) | 1.88 (p = 0.182) | 1.47 (p = 0.561) |
Reported Experiencing New or Worsening Mental Health Problems or Symptoms | 23 (25.0%) | 0 | 1.59 (p = 0.379) | 1.48 (p = 0.442) | 2.01 (p = 0.313) |
Reported Having More Difficulty Accessing Mental Health Services | 17 (56.7%) | 62 | Unable to test due to small N | Unable to test due to small N | Unable to test due to small N |
Reported Increasing the Number of Times Injected Per Day * | 24 (28.2%) | 7 | 2.82 (p = 0.086) | 2.19 (p = 0.162) | 1.87 (p = 0.408) |
Reported a Decrease in Purity of Drugs Purchased * | 38 (43.7%) | 5 | 1.42 (p = 0.491) | 1.90 (p = 0.203) | 0.22 (p = 0.078) |
Reported a Decrease in Quality of Drugs Purchased * | 38 (44.2%) | 6 | 1.34 (p = 0.584) | 1.10 (p = 0.856) | 0.15 (p = 0.050) |
Reported More Fentanyl in Drugs Purchased * | 27 (32.1%) | 8 | 1.23 (p = 0.696) | 0.73 (p = 0.538) | 0.35 (p = 0.220) |
Reported Amount of Drugs Used Alone Has Increased Since Start of Pandemic * | 25 (29.1%) | 6 | 2.23 (p = 0.150) | 3.89 (p = 0.017) | 1.24 (p = 0.773) |
Reported that Amount of Worrying about Overdosing Has Increased * | 13 (15.1%) | 6 | 1.82 (p = 0.467) | 1.47 (p = 0.615) | 1.53 (p = 0.673) |
Reported Having More Triggers than Normal * | 26 (29.2%) | 3 | 0.47 (p = 0.149) | 0.69 (p = 0.473) | 0.84 (p = 0.811) |
Reported Trying to Stop but Being Unable * | 20 (23.5%) | 7 | 2.84 (p = 0.107) | 2.67 (p = 0.099) | 1.90 (p = 0.396) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Williams, L.D.; Lee, E.; Latkin, C.; Mackesy-Amiti, M.E.; Kaufmann, M.; Copulsky, E.; Kaplan, C.; Boodram, B. Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs. Int. J. Environ. Res. Public Health 2022, 19, 5351. https://doi.org/10.3390/ijerph19095351
Williams LD, Lee E, Latkin C, Mackesy-Amiti ME, Kaufmann M, Copulsky E, Kaplan C, Boodram B. Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs. International Journal of Environmental Research and Public Health. 2022; 19(9):5351. https://doi.org/10.3390/ijerph19095351
Chicago/Turabian StyleWilliams, Leslie D., Eunhye Lee, Carl Latkin, Mary Ellen Mackesy-Amiti, Maggie Kaufmann, Elizabeth Copulsky, Charlie Kaplan, and Basmattee Boodram. 2022. "Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs" International Journal of Environmental Research and Public Health 19, no. 9: 5351. https://doi.org/10.3390/ijerph19095351
APA StyleWilliams, L. D., Lee, E., Latkin, C., Mackesy-Amiti, M. E., Kaufmann, M., Copulsky, E., Kaplan, C., & Boodram, B. (2022). Economic Challenges and Behavioral and Mental Health Risks for Overdose during the COVID-19 Pandemic among People Who Inject Drugs. International Journal of Environmental Research and Public Health, 19(9), 5351. https://doi.org/10.3390/ijerph19095351